Sonova Holding AG

OTCPK:SONV.F Stock Report

Market Cap: US$17.3b

Sonova Holding Valuation

Is SONV.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SONV.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SONV.F ($278.03) is trading below our estimate of fair value ($417.33)

Significantly Below Fair Value: SONV.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SONV.F?

Other financial metrics that can be useful for relative valuation.

SONV.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.7x
Enterprise Value/EBITDA19.9x
PEG Ratio2.4x

Price to Earnings Ratio vs Peers

How does SONV.F's PE Ratio compare to its peers?

The above table shows the PE ratio for SONV.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average38.7x
STE STERIS
36.2x13.2%US$20.5b
PODD Insulet
59.2x17.5%US$12.2b
RMD ResMed
33.3x13.1%US$31.9b
ZBH Zimmer Biomet Holdings
26x11.4%US$25.0b
SONV.F Sonova Holding
26.1x10.7%US$15.7b

Price-To-Earnings vs Peers: SONV.F is good value based on its Price-To-Earnings Ratio (26.1x) compared to the peer average (39.9x).

Price to Earnings Ratio vs Industry

How does SONV.F's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.0%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.0%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: SONV.F is good value based on its Price-To-Earnings Ratio (26.1x) compared to the US Medical Equipment industry average (37.2x).

Price to Earnings Ratio vs Fair Ratio

What is SONV.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SONV.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio26.1x
Fair PE Ratio43.5x

Price-To-Earnings vs Fair Ratio: SONV.F is good value based on its Price-To-Earnings Ratio (26.1x) compared to the estimated Fair Price-To-Earnings Ratio (43.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SONV.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$278.03
US$296.43
+6.6%
11.3%US$355.65US$218.86n/a17
Apr ’25US$296.29
US$300.11
+1.3%
12.0%US$360.37US$221.77n/a17
Mar ’25US$306.25
US$307.97
+0.6%
13.4%US$369.90US$227.63n/a17
Feb ’25US$320.11
US$311.37
-2.7%
14.7%US$378.92US$233.18n/a16
Jan ’25US$322.16
US$296.39
-8.0%
12.7%US$368.95US$230.59n/a15
Dec ’24US$285.48
US$296.65
+3.9%
13.4%US$388.30US$228.41n/a16
Nov ’24US$230.16
US$274.29
+19.2%
15.8%US$373.78US$214.38n/a16
Oct ’24US$236.80
US$277.21
+17.1%
16.3%US$372.81US$213.82n/a16
Sep ’24US$256.41
US$294.89
+15.0%
15.4%US$384.91US$226.76n/a17
Aug ’24US$284.02
US$294.89
+3.8%
15.4%US$384.91US$226.76n/a17
Jul ’24US$269.80
US$285.31
+5.7%
14.8%US$370.69US$218.38n/a17
Jun ’24US$262.00
US$274.69
+4.8%
14.6%US$353.15US$198.98n/a18
May ’24US$314.75
US$282.26
-10.3%
15.1%US$361.62US$197.58US$265.6516
Apr ’24US$285.00
US$281.53
-1.2%
15.2%US$361.03US$197.26US$296.2916
Mar ’24US$242.05
US$281.79
+16.4%
15.4%US$359.44US$196.39US$306.2516
Feb ’24US$253.20
US$281.79
+11.3%
15.4%US$359.44US$196.39US$320.1116
Jan ’24US$235.00
US$308.14
+31.1%
20.7%US$484.49US$194.12US$322.1616
Dec ’23US$255.25
US$306.75
+20.2%
20.0%US$473.89US$189.87US$285.4815
Nov ’23US$246.25
US$306.60
+24.5%
16.9%US$452.04US$256.16US$230.1614
Oct ’23US$223.34
US$347.27
+55.5%
13.6%US$466.49US$266.42US$236.8013
Sep ’23US$258.88
US$349.20
+34.9%
13.8%US$464.80US$265.45US$256.4113
Aug ’23US$355.00
US$387.89
+9.3%
11.8%US$469.22US$302.39US$284.0212
Jul ’23US$314.85
US$391.00
+24.2%
15.6%US$491.46US$268.74US$269.8013
Jun ’23n/a
US$382.44
0%
17.0%US$489.95US$260.61US$262.0016
May ’23US$360.00
US$389.66
+8.2%
19.4%US$493.41US$238.31US$314.7517

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.